• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Modern Rheumatology Case Reports

    Modern Rheumatology Case Reports

    JournalISSN 2472-5625eISSN 2472-5625中科院 医学 4区

    年发文量

    研究主题

    论文(765)

    排序
    1A Unique Case of Granulomatosis with Polyangiitis Presenting with Proximal Muscle Weakness
    Jason L Chen, Kaitlyn Baber, Jared Stillman, Xiaoshan Gong, Natasha Khona, Trevor Huff, Saher Khalid, Faryal Razzaq, Carlos Tafich-Rios, Hasan Ozgur, Bujji Ainapurapu

    Abstract Granulomatosis with polyangiitis (GPA) is a subtype of antineutrophilic cytoplasmic antibodies-associated vasculitis that can have a heterogeneous clinical presentation. Although classically involving the respiratory tract and kidneys, GPA can rarely present with predominant skeletal muscle involvement. This is unique given that skeletal muscle involvement has predominantly been associated with eosinophilic GPA and microscopic polyangiitis in the literature. Here, we detail a patient who presented with acute, progressive bilateral proximal lower extremity weakness and thigh pain, along with weight loss and transiently elevated creatine kinase and aldolase. The clinical course was complicated by temporally distinct focal cerebral infarctions, alongside findings of rhinosinusitis and multiple pulmonary nodules. Serology was positive for proteinase 3-antineutrophilic cytoplasmic antibodies, and magnetic resonance angiography of the brain utilising black blood sequence confirmed central nervous system vasculitis. Crucially, targeted biopsies of the right vastus lateralis and lung nodule demonstrated fibrinoid necrosis and necrotising granulomatous inflammation, respectively. Together, this histopathological evidence strongly suggests the proximal myopathy and central nervous system infarction were the result of profound, systemic microvascular ischaemia. This case highlights that GPA may initially manifest as muscle weakness. Recognising this atypical presentation is crucial to ensure timely initiation of treatment to reduce disease-associated morbidity and mortality.

    2026
    引用
    AI阅读
    加入学术空间
    2Primary Erythromelalgia Associated with an SCN9A Variant Can Mimic Systemic Lupus Erythematosus in Skin Manifestations: A Case Report
    Atsuko Tomikawa, Kazuyuki Meguro, Keishi Etori,Tomoki Suichi, Makoto Yamamoto, Rena Oguma, Yoshihide Okano,Eri Sato, Kazutaka Noda,Keisuke Matsusaka, Jun-ichiro Ikeda,Hiroshi Nakajima

    Abstract Primary erythromelalgia (PEM) is a rare autosomal dominant disorder characterised by episodic erythema and burning pain of the extremities, typically triggered by exercise or fatigue. PEM usually begins in childhood and is caused by gain-of-function variants in SCN9A, which encodes the voltage-gated sodium channel Nav1.7. The disease concept of PEM, however, is largely unrecognised among rheumatologists. Here, we report a 20-year-old woman who had experienced recurrent burning pain and redness of the extremities since around age 10. She also exhibited livedo-like rash, leukopenia, and hypocomplementemia and tested positive for antinuclear antibodies. Nerve conduction studies showed abnormalities interpreted as compatible with multifocal mononeuropathy. Based on these findings, she was diagnosed with systemic lupus erythematosus and treated with 20 mg of prednisolone; however, the painful erythema of the extremities did not improve. Given a family history of similar episodic symptoms in her father, PEM was suspected. Genetic testing identified a heterozygous SCN9A p.G856D variant, supporting the diagnosis of autosomal dominant PEM. Direct immunofluorescence/lupus band testing of the biopsied lower-leg lesion was interpreted as negative. This case highlights that SCN9A-associated PEM may present with lupus-like cutaneous erythema in young patients, potentially leading to misdiagnosis and ineffective immunosuppression. PEM should be considered in patients with childhood-onset, trigger-induced painful erythema of the extremities, particularly when there is family history or poor response to steroids.

    2026
    引用
    AI阅读
    加入学术空间
    3Golimumab-induced Lupus Erythematosus Complicated by Angioedema and Anti–galactocerebroside Antibody-Positive Dysphagia
    Makoto Misaki, Toshiaki Shimizu, Reo Yamazato, Yuichi Suwa, Yoichi Yasunaga,Keishi Fujio

    Abstract Drug-induced lupus erythematosus is an autoimmune condition that resembles systemic lupus erythematosus and occurs after exposure to specific medications, including tumour necrosis factor alpha inhibitors. We report a rare case of golimumab-induced lupus erythematosus complicated by macrophage activation syndrome, angioedema, and severe dysphagia with anti-galactocerebroside antibodies detected. A 57-year-old woman with ulcerative colitis developed facial swelling, malar rash, arthritis, pancytopenia, hyperferritinaemia, hypocomplementaemia, and proteinuria after long-term treatment with tumour necrosis factor alpha inhibitors, most recently golimumab. Bone marrow examination demonstrated haemophagocytosis, confirming macrophage activation syndrome. Computed tomography and endoscopy revealed soft tissue and oesophageal oedema consistent with angioedema. Despite improvement of systemic inflammation following high-dose glucocorticoids and intravenous cyclophosphamide, severe dysphagia persisted. A videofluoroscopic swallowing study demonstrated pharyngeal muscle dysfunction, and serum testing detected anti-galactocerebroside immunoglobulin G antibodies. Neurological imaging and electrophysiological studies were unremarkable. Swallowing function gradually recovered after discontinuation of golimumab. This case highlights that golimumab-induced lupus erythematosus may trigger multiple autoimmune complications, including macrophage activation syndrome, angioedema, and antibody-associated neuromuscular dysphagia. Awareness of these potentially life-threatening manifestations is essential for early recognition and appropriate management in patients receiving tumour necrosis factor alpha inhibitors.

    2026
    引用
    AI阅读
    加入学术空间
    4Successful Use of a Janus-kinase (JAK) Inhibitor in Chronic Chikungunya Arthritis Refractory to Conventional Synthetic DMARDs: A Case Report
    Jobson Lopes de Oliveira, José Kennedy Amaral, Igor Albuquerque Nogueira, Luis Arthur Brasil Gadelha Farias, Robert T Schoen

    Abstract Chronic chikungunya arthritis is a debilitating post-viral inflammatory condition that clinically mimics rheumatoid arthritis and often requires long-term treatment with disease-modifying antirheumatic drugs. Treatment options are limited when conventional synthetic disease-modifying antirheumatic drugs are not tolerated or lose efficacy. We report the case of a 50-year-old Brazilian woman with serologically confirmed chikungunya virus infection who developed chronic chikungunya arthritis with a rheumatoid arthritis–like phenotype. Following an acute febrile illness accompanied by rash and negative dengue serology, she was initially managed with symptomatic analgesics, followed by prednisone and hydroxychloroquine. Despite this treatment, the disease activity score in 28 joints calculated with C-reactive protein was elevated at 6.78. Methotrexate was introduced but was discontinued after 3 weeks due to drug-induced pneumonitis. She later failed leflunomide therapy after 12 months, with a score of 4.33. Baricitinib (4 mg/day), a Janus kinase 1 and 2 inhibitor, was then initiated, resulting in marked clinical and laboratory improvement: the disease activity score decreased to 1.90 over 1 year, C-reactive protein normalised, the erythrocyte sedimentation rate declined progressively, and morning stiffness resolved, with no infectious complications. This case suggests that Janus kinase inhibition may be a therapeutic option for selected patients with chronic chikungunya arthritis refractory to conventional treatment.

    2026
    引用
    AI阅读
    加入学术空间
    5Sjögren Disease and Idiopathic Inflammatory Myopathy Overlap Presenting As Complement-Mediated Thrombotic Microangiopathy/atypical Haemolytic Uremic Syndrome with a Complement Factor B Variant: A Case Report
    Momoka Hasegawa,Yoshia Miyawaki,Moe Sakamoto-Tokunaga, Masaki Matoba, Megumi Maeda, Tomokazu Tamura,Natsuki Kubota,Yuya Terajima,Kei Hirose,Kazuya Matsumoto, Manami Watanabe,Takato Nakadoi,

    ABSTRACT Complement-mediated thrombotic microangiopathy (CM-TMA) is often triggered by autoimmune diseases; however, reports of CM-TMA in patients with Sjögren disease and idiopathic inflammatory myopathy are limited. We describe the case of a 48-year-old woman with overlapping Sjögren disease and idiopathic inflammatory myopathy who presented with interstitial lung disease. After the initiation of combination therapy with a calcineurin inhibitor, intravenous cyclophosphamide, and glucocorticoids, she developed progressive thrombocytopenia with schistocytosis, haemolytic anaemia, and acute renal dysfunction. Laboratory testing revealed preserved disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13 (ADAMTS13) activity (49%) with negative ADAMTS13 inhibitor and Shiga toxins. Despite therapeutic plasma infusion and plasma exchange, she developed severe cardiac dysfunction and abdominal pain, with progressive haematologic and renal dysfunctions requiring haemodialysis. Based on a clinical diagnosis of CM-TMA, eculizumab was initiated, resulting in gradual improvement in haemolysis markers and platelet counts. However, she developed severe multiorgan complications, including a cerebellar haemorrhage, acute pancreatitis, and coagulopathy, and ultimately died. Genetic testing performed during the clinical course identified a complement factor B p.Arg74His variant. This case represents an instance of CM-TMA associated with a Sjögren disease/idiopathic inflammatory myopathy overlap and a complement factor B variant of uncertain pathogenic significance, suggesting that multiple converging factors may contribute to CM-TMA development.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 765 篇论文

    高被引作者

    作者引用发文
    Jeffrey P. Houchins11261
    Bruce A. McClure11261
    Shin-Ichiro Ohmura9811
    Yoshiya Tanaka7630
    Nagamura Norihiro712
    Tomoyuki Sugitani691
    Taio Naniwa685
    Yukio Nakamura569
    Takako Suzuki547
    Toru Yamabe524

    高产作者

    作者引用发文
    Yoshiya Tanaka7630
    Shingo Nakayamada4818
    Kazuhisa Nakano5215
    Ippei Miyagawa2815
    Ran Nakashima1614
    Yoshifumi Ubara1714
    Hajime Yoshifuji1614
    Tatsuya Suwabe1613
    Naoki Sawa1713
    Shigeru Iwata3112

    相关期刊

    Reumatologia clinica
    Case reports in rheumatology
    European journal of rheumatology
    Reumatismo
    Case Reports in Immunology
    Revista Colombiana de Reumatologia
    Arthritis & Rheumatism
    Reumatología Clínica (English Edition)
    Revista Colombiana de Reumatología (English Edition)
    Mediterranean Journal of Rheumatology